Isofol Medical
ISOFOL | XSTO
Overview
Corporate Details
- ISIN(s):
- SE0009581051
- LEI:
- 549300MCXYAHG7VBHX75
- Country:
- Sweden
- Address:
- C/O Biotech Center, Arvid Wallgrens, 413 46 Göteborg
- Website:
- https://isofolmedical.com/
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
Isofol Medical AB (publ), founded in 2008, is a biotech company that is developing a new drug candidate for the treatment of advanced colorectal cancer. Colorectal cancer (CRC) is the third most common form of cancer worldwide and there is a very high need for more effective drugs to treat this disease. Vision: “Isofol will help extend life and improve the quality of life for cancer patients” Arfolitixorin is being developed and commercialized through a global licensing agreement with Merck & Cie in Germany. The licensing agreement also grants Isofol access to the unique patented manufacturing process for arfolitixorin.
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-05 08:30 |
Share Issue/Capital Change
Isofol offentliggör slutliga villkor i företrädesemission samt för en potentiel…
|
Swedish | 142.5 KB | |
| 2025-06-05 08:30 |
Share Issue/Capital Change
Isofol announces final terms of the rights issue and the potential overallotmen…
|
English | 167.4 KB | |
| 2025-05-21 16:40 |
Declaration of Voting Results & Voting Rights Announcements
Bulletin from annual general meeting in Isofol Medical AB (publ) held on May 21…
|
English | 95.5 KB | |
| 2025-05-21 16:40 |
Declaration of Voting Results & Voting Rights Announcements
Kommuniké från årsstämma i Isofol Medical AB (publ) den 21 maj 2025
|
Swedish | 90.1 KB | |
| 2025-05-21 08:00 |
Interim Report
|
Swedish | 725.3 KB | |
| 2025-05-21 08:00 |
Regulatory News Service
|
English | 722.9 KB | |
| 2025-05-12 08:45 |
General Meeting Notice
Kallelse till extra bolagsstämma den 11 juni 2025 i Isofol Medical AB (publ)
|
Swedish | 135.1 KB | |
| 2025-05-12 08:45 |
Regulatory News Service
Notice to attend the Extraordinary General Meeting held on June 11, 2025 in Iso…
|
English | 62.5 KB | |
| 2025-05-12 08:30 |
Transaction in Own Shares
Styrelsen i Isofol beslutar om en fullt garanterad Företrädesemission av units …
|
Swedish | 153.0 KB | |
| 2025-05-12 08:30 |
Inside Information Statement
The Board of Directors of Isofol resolves on a fully guaranteed Rights Issue of…
|
English | 155.2 KB | |
| 2025-03-21 12:05 |
Inside Information Statement
Isofol receives regulatory approval to initiate clinical study of arfolitixorin
|
English | 68.0 KB | |
| 2025-03-21 12:05 |
Inside Information Statement
Isofol erhåller myndighetsgodkännande för att inleda klinisk studie med arfolit…
|
Swedish | 69.2 KB | |
| 2025-02-19 08:00 |
Quarterly Report
|
Swedish | 599.9 KB | |
| 2025-02-19 08:00 |
Annual Report
|
English | 2.7 MB | |
| 2024-11-19 15:40 |
Regulatory News Service
Isofol appoints nomination committee ahead of the Annual General Meeting 2025
|
English | 116.9 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2020-06-05 | Gustaf Albèrt | Other | Other | 1,542 | 5,397.00 SEK |
| 2020-06-02 | HealthCom GmbH | Other | Buy | 133,336 | 466,676.00 SEK |
| 2020-06-01 | Gustaf Albèrt | Other | Other | 10,664 | 37,324.00 SEK |
| 2020-06-01 | Sven Eriksson | Other | Other | 9,332 | 32,662.00 SEK |
| 2020-06-01 | Sven Eriksson | Other | Other | 9,223 | 32,280.50 SEK |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
1NKEMIA | Spain | IKM | |
|
2cureX AB | Sweden | 2CUREX | |
|
4SC AG | Germany | VSC | |
|
Abera Bioscience AB | Sweden | ABERA | |
|
ABIONYX Pharma | France | ABNX | |
|
Abliva | Sweden | ABLI | |
|
AB Science | France | AB | |
|
Acticor Biotech | France | ALACT | |
|
Active Biotech | Sweden | ACTI | |
|
AcuCort AB | Sweden | ACUC |